Literature DB >> 20096038

Recent insights into cerebral cavernous malformations: the molecular genetics of CCM.

Florence Riant1, Francoise Bergametti, Xavier Ayrignac, Gwenola Boulday, Elisabeth Tournier-Lasserve.   

Abstract

Cerebral cavernous malformations (CCM) are vascular lesions which can occur as a sporadic (80% of the cases) or familial autosomal dominant form (20%). Three CCM genes have been identified: CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10. Almost 80% of CCM patients affected with a genetic form of the disease harbor a heterozygous germline mutation in one of these three genes. Recent work has shown that a two-hit mechanism is involved in CCM pathogenesis which is caused by a complete loss of any of the three CCM proteins within endothelial cells lining the cavernous capillary cavities. These data were an important step towards the elucidation of the mechanisms of this condition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096038     DOI: 10.1111/j.1742-4658.2009.07535.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  77 in total

Review 1.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

2.  Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome.

Authors:  A Kerpel; M Yalon; M Soudack; J Chiang; A Gajjar; K E Nichols; Z Patay; S Shrot; C Hoffmann
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-30       Impact factor: 3.825

3.  Case report: glioblastoma multiforme complicating familial cavernous malformations.

Authors:  D M Wilson; B Cohen; K Keshari; H Vogel; G Steinberg; W Dillon
Journal:  Clin Neuroradiol       Date:  2013-08-14       Impact factor: 3.649

4.  PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.

Authors:  Svetlana M Stamatovic; Nikola Sladojevic; Richard F Keep; Anuska V Andjelkovic
Journal:  Acta Neuropathol       Date:  2015-09-18       Impact factor: 17.088

5.  Expression of CCM2 and CCM3 during mouse gonadogenesis.

Authors:  Aylin Yaba; N Ece Gungor Ordueri; Gamze Tanriover; Pinar Sahin; Necdet Demir; Ciler Celik-Ozenci
Journal:  J Assist Reprod Genet       Date:  2015-09-19       Impact factor: 3.412

Review 6.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

7.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

8.  Two-hit mechanism in cerebral cavernous malformation? A case of monozygotic twins with a CCM1/KRIT1 germline mutation.

Authors:  Philipp Dammann; Ute Hehr; Sabine Weidensee; Yuan Zhu; Rüdiger Gerlach; Ulrich Sure
Journal:  Neurosurg Rev       Date:  2013-04-13       Impact factor: 3.042

9.  Genetic Screening of Pediatric Cavernous Malformations.

Authors:  Elisa Merello; Marco Pavanello; Alessandro Consales; Samantha Mascelli; Alessandro Raso; Andrea Accogli; Armando Cama; Capra Valeria; Patrizia De Marco
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

Review 10.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.